iECURE

iECURE is an in vivo gene editing company that is mutation-agnostic, dedicated to treating devastating diseases with unmet needs. We are working closely with the world-class translational engine of the University of Pennsylvania’s Gene Therapy Program to advance our pipeline. Through in vivo editing, our approach focuses on inserting functional genes into a patient’s genome, enabling long-term stable expression of these genes. With our team’s proven track record, along with the deep expertise and translational gene medicine engine of the University of Pennsylvania, reversing the course of these devastating diseases is now within reach.